The U.S. National Science Advisory Board for Biosecurity weighed in publicly for the first time yesterday about research on mammalian-adapted H5N1 influenza, and the Board’s verdict was that the research is important and needs to go forward, but must be done very carefully, with oversight, and without releasing potentially dangerous details to the general public.
Perhaps most importantly, aside from the NSABB giving a general thumbs up to current and future H5N1 research, the Board cried out a clear warning for the world to prepare for a naturally-generated H5N1 threat. As acting NSABB chairman Paul S. Keim said in a Q&A that accompanied the Board’s statement in Nature, “It is important to convey how unprepared, on every level, the world is for a H5N1 pandemic.” A highly pathogenic form of H5N1 flu, which the recent work by Kawaoka and Fouchier made clear is a potential natural development, would produce an “unimaginable catastrophe” worldwide, the NSABB said in its statement yesterday.
Courtesy Library of Congress
|
The Board also coined a new phrase to categorize the H5N1 work: “dual use research.” Dual in that the research “could be used for good or bad purposes.” That, of course, is why the Board wants the methods part of the work kept off the public record. “Publishing these experiments in detail would provide information to some person, organization, or government that would help them to develop similar mammal-adapted influenza A/H5N1 viruses for harmful purposes,” the NSABB said. The Board said the threat from this work is so high that the life sciences have now “reached a crossroads,” similar to what physics faced in the 1940s with the development of nuclear weapons.
But despite the threat from widespread release of the research methods—a risk that the NSABB believes can be blunted by simply not publishing the information—the Board firmly endorsed the work done so far and its continuation. That contrasts with the continued call from some critics to shut it down completely.
H5N1 research is “a well-intended effort to discover evolutionary routes by which influenza A/H5N1 viruses might adapt to humans. Such knowledge may be valuable for improving the public-health response to a looming natural threat,” the NSABB said. “We acknowledge that there are clear benefits to be realized for the public good in alerting humanity of this potential threat and in pursuing those aspects of this work that will allow greater preparedness and the potential development of novel strategies leading to future disease control.”
—Mitchel Zoler (on Twitter @mitchelzoler)
Specialty Focus
Cardiovascular Disease
Diabetes, Endocrinology & Metabolism
Gastroenterology
Hematology/Thrombosis
Imaging
Infectious Diseases
Nephrology
Neurology & Pain
Palliative/Hospice
Pediatrics
Perioperative Medicine
Practice Trends
Psychiatry
Pulmonary Disease
Trauma
| May 11 - 21 Departs Civitavecchia, | Rheumatology and Orthopaedics |
| May 11 - 21 Departs Civitavecchia, | Rheumatology and Orthopaedics |
| May 12 - 21 Departs Oslo, | Pain Management/Neurology/Compliance |
| May 18 - 23 San Francisco, CA | American Thoracic Society (ATS): International Conference |
| May 19 - 22 New York, NY | American Society of Hypertension (ASH): Annual Scientific Meeting |
| May 19 - 22 San Diego, CA | Digestive Disease Week (DDW 2012) |
| May 19 - 22 Sao Paulo, | XXX RADLA 2012: Annual Meeting of Latin American Dermatologists |
| May 19 - 24 Atlanta, GA | American Urological Association (AUA): Annual Meeting |
| May 19 - 23 Stockholm, | European Calcified Tissue Society (ECTS): Annual Congress |
| May 20 - 23 Brisbane, | Australasian College of Dermatologists: Annual Scientific Meeting |